Literature DB >> 15575895

Activation of A3 adenosine receptor provides lung protection against ischemia-reperfusion injury associated with reduction in apoptosis.

Julia Rivo1, Evelyne Zeira, Eithan Galun, Idit Matot.   

Abstract

Apoptosis has been described in various models of ischemia-reperfusion (IR) injury, including lung transplantation. A3 adenosine receptor (AR) has been linked to a variety of apoptotic processes. The effect of A3AR activation on lung injury and apoptosis, following IR, has not been reported to date. In a spontaneously breathing cat model, in which the left lower lobe of the lung was isolated and subjected to 2 h of ischemia and 3 h of reperfusion, we tested the effect of IB-MECA, a selective A3AR agonist, on lung apoptosis and injury. Significant increase in the extent of apoptosis was observed following lung reperfusion. IB-MECA, administered before IR, and before or with reperfusion, markedly (p < 0.01) attenuated indices of injury and apoptosis including the percentage of injured alveoli, wet/dry weight ratio, myeloperoxidase activity, in situ terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) positive cells, and caspase 3 activity and expression. The protective effects of IB-MECA were completely blocked by pretreatment with the selective A3AR antagonist MRS-1191. In summary, even when given after the onset of ischemia, the A3AR agonist IB-MECA conferred a powerful protection against reperfusion lung injury, which was associated with decreased apoptosis. This suggests a potentially important role for A3AR in lung IR injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15575895     DOI: 10.1111/j.1600-6143.2004.00620.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  17 in total

Review 1.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

2.  Protective effect of adenosine receptors against lipopolysaccharide-induced acute lung injury.

Authors:  Joyce N Gonzales; Boris Gorshkov; Matthew N Varn; Marina A Zemskova; Evgeny A Zemskov; Supriya Sridhar; Rudolf Lucas; Alexander D Verin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-01-10       Impact factor: 5.464

Review 3.  Pulmonary Endothelial Cell Apoptosis in Emphysema and Acute Lung Injury.

Authors:  Eboni Chambers; Sharon Rounds; Qing Lu
Journal:  Adv Anat Embryol Cell Biol       Date:  2018       Impact factor: 1.231

4.  Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury.

Authors:  Leo M Gazoni; Dustin M Walters; Eric B Unger; Joel Linden; Irving L Kron; Victor E Laubach
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-15       Impact factor: 5.209

Review 5.  Targeting of adenosine receptors in ischemia-reperfusion injury.

Authors:  Victor E Laubach; Brent A French; Mark D Okusa
Journal:  Expert Opin Ther Targets       Date:  2010-11-29       Impact factor: 6.902

6.  A3 adenosine receptor signaling influences pulmonary inflammation and fibrosis.

Authors:  Eva Morschl; Jose G Molina; Jonathan B Volmer; Amir Mohsenin; Ralph S Pero; Jeong-Soo Hong; Farrah Kheradmand; James J Lee; Michael R Blackburn
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-27       Impact factor: 6.914

7.  Sustained adenosine exposure causes lung endothelial apoptosis: a possible contributor to cigarette smoke-induced endothelial apoptosis and lung injury.

Authors:  Qing Lu; Pavlo Sakhatskyy; Julie Newton; Paul Shamirian; Vivian Hsiao; Sean Curren; Gustavo Andres Gabino Miranda; Mesias Pedroza; Michael R Blackburn; Sharon Rounds
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-01-11       Impact factor: 5.464

Review 8.  Mechanisms of induction of adenosine receptor genes and its functional significance.

Authors:  Cynthia St Hilaire; Shannon H Carroll; Hongjie Chen; Katya Ravid
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

9.  The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.

Authors:  A Ochaion; S Bar-Yehuda; S Cohen; H Amital; K A Jacobson; B V Joshi; Z G Gao; F Barer; R Patoka; L Del Valle; G Perez-Liz; P Fishman
Journal:  Biochem Pharmacol       Date:  2008-06-17       Impact factor: 5.858

10.  Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation.

Authors:  Ashish K Sharma; Joel Linden; Irving L Kron; Victor E Laubach
Journal:  Respir Res       Date:  2009-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.